JP2024518712A5 - - Google Patents
Info
- Publication number
- JP2024518712A5 JP2024518712A5 JP2023562492A JP2023562492A JP2024518712A5 JP 2024518712 A5 JP2024518712 A5 JP 2024518712A5 JP 2023562492 A JP2023562492 A JP 2023562492A JP 2023562492 A JP2023562492 A JP 2023562492A JP 2024518712 A5 JP2024518712 A5 JP 2024518712A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- approximately
- patient
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173219P | 2021-04-09 | 2021-04-09 | |
| US63/173,219 | 2021-04-09 | ||
| US202163252542P | 2021-10-05 | 2021-10-05 | |
| US63/252,542 | 2021-10-05 | ||
| US202263297960P | 2022-01-10 | 2022-01-10 | |
| US63/297,960 | 2022-01-10 | ||
| PCT/US2022/024087 WO2022217100A1 (en) | 2021-04-09 | 2022-04-08 | Treatment of cancer with kdm4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518712A JP2024518712A (ja) | 2024-05-02 |
| JP2024518712A5 true JP2024518712A5 (https=) | 2025-04-16 |
Family
ID=83545127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562492A Pending JP2024518712A (ja) | 2021-04-09 | 2022-04-08 | Ｋｄｍ４阻害剤による癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250025451A1 (https=) |
| EP (1) | EP4319748A4 (https=) |
| JP (1) | JP2024518712A (https=) |
| AU (1) | AU2022254741A1 (https=) |
| CA (1) | CA3214399A1 (https=) |
| WO (1) | WO2022217100A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600301B1 (en) | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| KR20250067936A (ko) * | 2022-09-21 | 2025-05-15 | 셀진 코포레이션 | 3-(｛[(4r)-7-｛메틸[4-(프로판-2-일)페닐]아미노｝-3,4-디하이드로-2h-1-벤조피란-4-일]메틸｝아미노)피리딘-4-카르복실산l-라이신 염의 결정형, 히스톤 탈메틸화효소 억제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307643D0 (en) * | 2003-04-02 | 2003-05-07 | Cyclacel Ltd | Markers |
| UY35395A (es) * | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
| SI3160952T1 (sl) * | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| EP3600301B1 (en) * | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| WO2019083594A1 (en) * | 2017-08-21 | 2019-05-02 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES |
| UY38349A (es) * | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| WO2023023112A1 (en) * | 2021-08-18 | 2023-02-23 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
-
2022
- 2022-04-08 JP JP2023562492A patent/JP2024518712A/ja active Pending
- 2022-04-08 WO PCT/US2022/024087 patent/WO2022217100A1/en not_active Ceased
- 2022-04-08 EP EP22785559.0A patent/EP4319748A4/en active Pending
- 2022-04-08 US US18/554,283 patent/US20250025451A1/en active Pending
- 2022-04-08 AU AU2022254741A patent/AU2022254741A1/en active Pending
- 2022-04-08 CA CA3214399A patent/CA3214399A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | Lysine demethylase 5B (KDM5B): a potential anti-cancer drug target | |
| Li et al. | KDM5 family as therapeutic targets in breast cancer: pathogenesis and therapeutic opportunities and challenges | |
| Madura et al. | Mucin-hypersecreting intraductal neoplasms of the pancreas: a precursor to cystic pancreatic malignancies | |
| JP2024518712A5 (https=) | ||
| WO2024088273A1 (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| WO2017200016A1 (ja) | Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬 | |
| JP7422084B2 (ja) | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 | |
| JP2024527109A5 (https=) | ||
| JP2022523214A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| WO2018214925A1 (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| CN104582706A (zh) | 辅助癌症治疗的方法 | |
| CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
| JP2024528705A (ja) | がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法 | |
| TW200934494A (en) | Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer | |
| JPWO2022270524A5 (https=) | ||
| EP2710038B1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| JP2022527499A5 (https=) | ||
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| JP2022527702A (ja) | 小細胞肺がんの治療におけるキアウラニブの使用 | |
| WO2016184909A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| JP2019519566A (ja) | がんの治療のための維持療法 | |
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 |